ConductScience.org, home
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
API referenceFor AI assistants

Trial · NCT03106779

Outcomes15

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 15 of 15

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYNumber of Participants With Major Molecular Response (MMR) Rate at 24 Weeks24 weeksFull Analysis Set (FAS): The FAS comprised of all randomized patients.ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYNumber of Participants With Major Molecular Response (MMR) Rate96 weeks after the last patient received the first study dose
SECONDARYComplete Cytogenetic Response Rate96 weeks after the last patient received the first study dose
SECONDARYTime to MMR96 weeks after the last patient received the first study dose
SECONDARYDuration of MMR96 weeks after the last patient received the first study dose
SECONDARYTime to CCyR96 weeks after the last patient received the first study dose
SECONDARYDuration of CCyR96 weeks after the last patient received the first study dose
SECONDARYTime to Treatment Failure96 weeks after the last patient received the first study dose
SECONDARYProgression Free Survival96 weeks after the last patient received the first study dose
SECONDARYOverall Survival96 weeks after the last patient received the first study dose
SECONDARYTrough Plasma Concentrations96 weeks after the last patient received the first study dose
SECONDARYPK Parameter: Cmax,96 weeks after the last patient received the first study dose
SECONDARYPK Parameter: Tmax96 weeks after the last patient received the first study dose
SECONDARYPK Parameter: AUC0-12h96 weeks after the last patient received the first study dose
SECONDARYPK Parameter: CL/F96 weeks after the last patient received the first study dose

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03106779/outcomes

API referenceFor AI assistants